| Literature DB >> 28856759 |
Caroline Laroye1,2,3,4, Sébastien Gibot2,4,5, Loïc Reppel1,3,4, Danièle Bensoussan1,3,4.
Abstract
Sepsis and septic shock are the leading cause of admission and mortality in non-coronary intensive care units. Currently, however, no specific treatments are available for this syndrome. Due to the failure of conventional treatments in recent years, research is focusing on innovative therapeutic agents, including cell therapy. One particular type of cell, mesenchymal stromal/stem cells (MSCs), has raised hopes for the treatment of sepsis. Indeed, their immunomodulatory properties, antimicrobial activity and capacity of protection against organ failure confer MSCs with a major advantage to treat the immune and inflammatory dysfunctions associated with sepsis and septic shock. After a brief description of the pathophysiology of sepsis and septic shock, the latest advances in the use of MSCs to treat sepsis will be presented. Stem Cells 2017;35:2331-2339.Entities:
Keywords: Immunomodulation; Mesenchymal stromal/stem cells; Organs failures; Sepsis and septic shock; Treatment
Mesh:
Year: 2017 PMID: 28856759 DOI: 10.1002/stem.2695
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277